UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 275

Sortiert nach

Triple-negative breast cancer—current status and future directions

Annals of oncology, 2009-12, Vol.20 (12), p.1913-1927

2009

Link zum Volltext

Verfügbarkeit prüfen

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel

Annals of oncology, 2017-11, Vol.28 (11), p.2768-2772

2017

Link zum Volltext

Verfügbarkeit prüfen

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression

Annals of oncology, 2014-08, Vol.25 (8), p.1551-1557

2014

Link zum Volltext

Verfügbarkeit prüfen

Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial

Annals of oncology, 2008-05, Vol.19 (5), p.861-870

2008

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysis

Annals of oncology, 2015-04, Vol.26 (4), p.688-695

2015

Link zum Volltext

Verfügbarkeit prüfen

Protroca: A non-interventional study on prophylaxis of chemotherapy induced neutropenia using lipegfilgrastim in non-selected breast cancer patients

Annals of oncology, 2019-05, Vol.30, p.iii67-iii67

2019

Link zum Volltext

Verfügbarkeit prüfen

Prognostic impact of anthracyclines and immune/proliferation markers in TNBC according to pCR after de-escalated neoadjuvant chemotherapy with 12 weeks of nab-paclitaxel/carboplatin or gemcitabine: Survival results of WSG-ADAPT-TN phase II trial

Annals of oncology, 2018-10, Vol.29, p.viii703-viii703

2018

Link zum Volltext

Verfügbarkeit prüfen

Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial

Annals of oncology, 2016-06, Vol.27 (6), p.1035-1040

2016

Link zum Volltext

Verfügbarkeit prüfen

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression

Annals of oncology, 2017-11, Vol.28 (11), p.2899-2899

2017

Link zum Volltext

Verfügbarkeit prüfen

Reply to letter to the editor ‘Primum non nocere’ by Templeton and Šeruga

Annals of oncology, 2015-10, Vol.26 (10), p.2198-2199

2015

Link zum Volltext

Verfügbarkeit prüfen

Corrections to "Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression"

Annals of oncology, 2017-11, Vol.28 (11), p.2899

2017

Link zum Volltext

Verfügbarkeit prüfen

Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer

Annals of oncology, 2014-01, Vol.25 (1), p.75-80

2014

Link zum Volltext

Verfügbarkeit prüfen

Five-year results of the prospective Phase III WSG PlanB trial confirm prognostic impact of 21-Gene Recurrence Score in high-risk HR+/HER2− early breast cancer (EBC) patients with 1-3 involved lymph nodes

Breast (Edinburgh), 2017-03, Vol.32, p.S93-S93

2017

Link zum Volltext

Verfügbarkeit prüfen

Chemotherapy (CT) decision in node-positive (N+), ER+, early breast cancer (EBC) after new ASCO Guideline – evidence for the 21-gene Recurrence Score (RS) assay

Breast (Edinburgh), 2017-03, Vol.32, p.S98-S98

2017

Link zum Volltext

Verfügbarkeit prüfen

1937 Clinical impact of risk classification by central/local grade or luminal-like subtype vs. Oncotype DX®: First prospective survival results from the WSG phase III planB trial

European journal of cancer (1990), 2015-09, Vol.51, p.S311-S311

2015

Link zum Volltext

Verfügbarkeit prüfen

Klinische Pathologie des Mammakarzinoms

Gynäkologie (Heidelberg, Germany), 2016-10, Vol.49 (10), p.737-745

2016

Link zum Volltext

Verfügbarkeit prüfen

P231 Luminal subtypes vs. early Ki-67 response and Oncotype DX® in early breast cancer: WSG-ADAPT study

Breast (Edinburgh), 2015-03, Vol.24, p.S104-S105

2015

Link zum Volltext

Verfügbarkeit prüfen

P246 Risk assessment by St.Gallen 2013 recommendation and Oncotype DX® : results from the WSG PlanB trial

Breast (Edinburgh), 2015-03, Vol.24, p.S110-S110

2015

Link zum Volltext

Verfügbarkeit prüfen

260 Primary Tumor in Breast Cancer and Its Phenotype in Positive Lymph Nodes and Later Disease Recurrence (metastatic Breast Cancer): Results of the PRIMET-trial (WSG/DETECT)

European journal of cancer (1990), 2012-03, Vol.48, p.S118-S118

2012

Link zum Volltext

Verfügbarkeit prüfen

Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer

European journal of nuclear medicine and molecular imaging, , Vol.26 (3), p.226-230

Link zum Volltext

Verfügbarkeit prüfen

PP 30 Prospective comparison of Recurrence Score, uPA/PAI-1, central grade and molecular subtyping in early breast cancer: first results from the WSG-Plan B trial (interim analysis)

European journal of cancer (1990), 2011, Vol.47, p.S33-S34

2011

Link zum Volltext

Verfügbarkeit prüfen

The EORTC 10041/BIG 03–04 MINDACT (Microarray in Node Negative and 1 to 3 Positive Lymph Node Disease May Avoid ChemoTherapy) Trial: Patients' Baseline Characteristics and Logistics Aspects After a Successful Accrual

European journal of cancer (1990), 2011, Vol.47, p.7-7

2011

Link zum Volltext

Verfügbarkeit prüfen

Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

The New England journal of medicine, 2005-10, Vol.353 (16), p.1659-1672

2005

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 275

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(232)
Mit Volltextzugriff
(246)

Publikationsform

Sprache

Englisch
(222)
Deutsch
(54)
Japanisch
(23)

Erscheinungsjahr

n.n

Thema

Science & Technology
(86)
Humans
(51)
Physics
(49)
Physical Sciences
(44)
Female
(42)
Astrophysics
(39)
Life Sciences & Biomedicine
(39)
Astronomy & Astrophysics
(32)
Sciences Of The Universe
(32)
High Energy Astrophysical Phenomena
(29)
Physics, Particles & Fields
(27)
Middle Aged
(24)
Augers
(21)
Breast Neoplasms - Drug Therapy
(21)
Oncology
(21)
Biological And Medical Sciences
(20)
Adult
(19)
Medical Sciences
(18)
Cosmic Rays
(17)
Astronomy And Astrophysics
(16)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Cancer Research
(30)
Annals Of Oncology
(26)
Journal Of Clinical Oncology
(19)
Gynäkologe
(18)
Breast
(13)
European Journal Of Cancer
(10)
Physical Review. D, Particles And Fields
(9)
Astroparticle Physics
(8)
Geburtshilfe Und Frauenheilkunde
(8)
Gynäkologie
(8)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Triple-negative breast cancer—current status and future directions

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression

Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2− early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2− trial

Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial

Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysis

Protroca: A non-interventional study on prophylaxis of chemotherapy induced neutropenia using lipegfilgrastim in non-selected breast cancer patients

Prognostic impact of anthracyclines and immune/proliferation markers in TNBC according to pCR after de-escalated neoadjuvant chemotherapy with 12 weeks of nab-paclitaxel/carboplatin or gemcitabine: Survival results of WSG-ADAPT-TN phase II trial

Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression

Reply to letter to the editor ‘Primum non nocere’ by Templeton and Šeruga

Corrections to "Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression"

Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer

Five-year results of the prospective Phase III WSG PlanB trial confirm prognostic impact of 21-Gene Recurrence Score in high-risk HR+/HER2− early breast cancer (EBC) patients with 1-3 involved lymph nodes

Chemotherapy (CT) decision in node-positive (N+), ER+, early breast cancer (EBC) after new ASCO Guideline – evidence for the 21-gene Recurrence Score (RS) assay

1937 Clinical impact of risk classification by central/local grade or luminal-like subtype vs. Oncotype DX®: First prospective survival results from the WSG phase III planB trial

Klinische Pathologie des Mammakarzinoms

P231 Luminal subtypes vs. early Ki-67 response and Oncotype DX® in early breast cancer: WSG-ADAPT study

P246 Risk assessment by St.Gallen 2013 recommendation and Oncotype DX® : results from the WSG PlanB trial

260 Primary Tumor in Breast Cancer and Its Phenotype in Positive Lymph Nodes and Later Disease Recurrence (metastatic Breast Cancer): Results of the PRIMET-trial (WSG/DETECT)

Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer

PP 30 Prospective comparison of Recurrence Score, uPA/PAI-1, central grade and molecular subtyping in early breast cancer: first results from the WSG-Plan B trial (interim analysis)

The EORTC 10041/BIG 03–04 MINDACT (Microarray in Node Negative and 1 to 3 Positive Lymph Node Disease May Avoid ChemoTherapy) Trial: Patients' Baseline Characteristics and Logistics Aspects After a Successful Accrual

Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

Suchergebnisse filtern